Restrictive cardiomyopathy: clinical overview

Article written and reviewed by Dr Luca Moretti

Restrictive cardiomyopathy identifies a heart in which the dominant problem is the inability of the ventricles to fill without a disproportionate increase in pressure. Ventricular cavities generally remain normal in size or reduced, whereas the atria dilate because they work against stiff chambers and are chronically exposed to backward pressure. Diastolic restriction can therefore cause pulmonary and systemic congestion even when ejection fraction appears preserved, because a normal percentage applied to a small end-diastolic volume does not guarantee adequate cardiac output.

This page introduces a heterogeneous group of diseases, not a single etiology. The monograph on restrictive cardiomyopathy systematically analyzes pathophysiology, differential diagnosis and treatment; the idiopathic form concerns cases in which the investigation identifies no cause, whereas the familial form addresses genes, penetrance and surveillance of relatives. This separation by purpose prevents confusion between the hemodynamic phenotype and the mechanism that produces it.

The label requires caution because a restrictive Doppler pattern may appear transiently in acute heart failure or persistently in the advanced stage of other cardiomyopathies. Amyloidosis, hemochromatosis, sarcoidosis, storage diseases, endomyocardial fibrosis and radiation injury can also produce similar physiology without all belonging to the same nosological category. The phenotype is not the etiology: recognizing restriction opens the investigation, it does not conclude it.

Primary restrictive cardiomyopathy is rare and represents only a small proportion of pediatric cardiomyopathies, but its importance is disproportionate to its prevalence. In children it may progress rapidly to pulmonary hypertension and transplantation, whereas in adults late diagnosis creates the risk of attributing dyspnea and edema to hypertension, age or atrial fibrillation. Clinical rarity does not justify a superficial pathway: heterogeneity itself requires method and multidisciplinary expertise.

What restriction really means

During normal diastole, the ventricle actively relaxes, creates a gradient that promotes filling and increases in volume with a limited rise in pressure. In restriction, relaxation may be slow, the wall may be intrinsically stiff, or the endocardium may limit expansion; in all these scenarios, the diastolic pressure-volume curve shifts upward and to the left. A small change in volume therefore generates a large change in pressure, defining the low compliance that underlies symptoms.

Early filling may become very rapid because the left atrium, subjected to high pressure, drives blood into a ventricle that can initially receive it. Flow then stops abruptly when the elastic limit is reached, producing a prominent E wave and shortened deceleration time on echocardiography in overt stages. This rapid and brief filling does not indicate good diastolic function but rather early exhaustion of ventricular capacity.

Atrial contraction plays an important role when sinus rhythm is present, but chronic pressure causes dilation, fibrosis and vulnerability to atrial fibrillation. Loss of atrial systole, an excessive heart rate that shortens diastole, or bradycardia that reduces cardiac output can all precipitate heart failure. Rhythm dependence explains why apparently modest changes in rate produce greater clinical deterioration than in a normal ventricle.

High pressures are transmitted to the pulmonary capillaries, pulmonary artery and venous system. Dyspnea, bendopnea and exercise intolerance reflect left-sided congestion and the inability to increase output; edema, ascites, hepatomegaly and jugular venous distention indicate right-sided involvement. Biventricular congestion may dominate the presentation long before global systolic function becomes clearly reduced.

The dilated, poorly contractile atrium promotes stasis, thrombi and thromboembolism, especially but not exclusively in the presence of atrial fibrillation. Functional mitral or tricuspid regurgitation further increases atrial volume load, whereas pulmonary hypertension may become a barrier to transplantation if vascular resistance does not remain reversible. Atrial remodeling is therefore not simply a radiological sign: it is an active part of progression.

A map of causes without shortcuts

Primary noninfiltrative forms include sarcomeric and cytoskeletal cardiomyopathies in which cellular stiffness, altered calcium sensitivity, myofibrillar disorganization and interstitial fibrosis produce the phenotype. TNNI3, TNNT2, MYH7, ACTC1, MYL2, MYL3, FLNC and DES belong to the genetic spectrum, but the weight of evidence is not identical for every gene and variant. Rigorous molecular causality requires classification according to current criteria and consistency with the familial phenotype.

Infiltrative or storage cardiomyopathies increase wall thickness and stiffness through extracellular material, cells or intracellular substances. Cardiac amyloidosis is the best-known example, but iron, sarcoid granulomas and some metabolic diseases follow different mechanisms and require specific tests. The expression thickened wall describes an image; it does not demonstrate true cardiomyocyte hypertrophy.

Endomyocardial forms affect the inner ventricular surface, with thrombosis, fibrosis and sometimes apical obliteration. Tropical endomyocardial fibrosis and Löffler disease share a final restrictive phase but differ in epidemiological context and the role of eosinophilia. Valves and the subvalvular apparatus may be involved, adding regurgitation to restriction. The geography of injury guides imaging, biopsy and surgical possibilities.

Mediastinal radiation, systemic fibrosing diseases and some drugs may simultaneously affect myocardium, pericardium, coronary arteries and valves. In these patients a single label is often insufficient because myocardial restriction and pericardial constriction may coexist. Mixed pathology should be actively sought when data do not converge or when previous cancer therapy explains several cardiac compartments.

The idiopathic definition is legitimate only after an assessment proportionate to age, phenotype and pre-test probability. It does not mean that no cause exists, but that available knowledge and methods have not demonstrated one. An apparently sporadic diagnosis may result from a de novo variant, incomplete penetrance in the parents or relatives who have not yet been studied. The term idiopathic is provisional and should be reassessed when new signs or genetic knowledge emerge.

Clinical clues that change the pathway

The history should reconstruct dyspnea, orthopnea, edema, syncope, palpitations and loss of functional capacity, but also neuropathy, orthostatic hypotension, proteinuria, carpal tunnel syndrome, hearing loss, muscle weakness and skin signs. These extracardiac elements are not ancillary: they link a common phenotype to treatable diseases and guide laboratory testing. A multisystem assessment reduces the risk of calling primary a cardiomyopathy that is an organ manifestation of systemic disease.

A pedigree of at least three generations searches for heart failure, transplantation, sudden death, early pacemaker implantation, stroke, myopathy and discordant diagnoses of hypertrophic cardiomyopathy. The same sarcomeric variant may produce restriction in one family member and hypertrophy in another, whereas DES may associate atrioventricular block with muscle disease. Intrafamilial variability makes the sum of phenotypes more informative than repetition of a single label.

On physical examination, blood pressure may be low or normal, the pulse pressure narrow and jugular venous pressure elevated; a third heart sound, atrioventricular murmurs and signs of congestion complete the picture. A positive Kussmaul sign is compatible with limited right-sided filling but does not reliably distinguish restriction from constriction. Hemodynamic clinical signs generate hypotheses that must be tested with Doppler and imaging; they do not replace comparison of mechanisms.

The ECG may show atrial enlargement, fibrillation, ST-T abnormalities, blocks or low voltage, the latter being particularly suggestive when it contrasts with apparently thick walls. However, normal voltage does not exclude amyloidosis and a minimally abnormal ECG does not exclude a genetic form. The ECG-imaging relationship is often more discriminating than a single finding considered in isolation.

BNP or NT-proBNP and troponin quantify stress and injury but are influenced by renal function, rhythm, age and amyloid type. Complete blood count, liver and renal function, ferritin with transferrin saturation, serum and urine immunofixation with free light chains, and targeted tests follow clinical probability. Directed laboratory testing must rapidly exclude AL amyloidosis when suspicion is plausible because therapeutic delay has immediate consequences.

Imaging and physiology as an integrated system

Echocardiography defines chamber dimensions, wall thickness, biventricular function, atria, valves, pulmonary pressure and the vena cava. In overt restriction it combines dilated atria with nondilated ventricles, a dominant E wave, short deceleration and reduced e' velocities on tissue Doppler, but no isolated parameter is sufficient. Multiparametric consistency distinguishes true restrictive physiology from variations related to loading conditions, age or technical error.

Longitudinal strain may reveal subclinical systolic dysfunction despite a normal ejection fraction. Relative apical sparing is a clue for amyloidosis but is not pathognomonic and its accuracy depends on the population studied. The right ventricle, valves and atria must be analyzed together with the left ventricle. Regional mechanics enrich diagnostic probability without turning a deformation map into etiologic typing.

Magnetic resonance measures volumes and function with high reproducibility and characterizes tissue using late gadolinium enhancement, native T1 and extracellular volume. Diffuse subendocardial patterns and difficulty with myocardial nulling suggest amyloid, whereas focal fibrosis or particular distributions may indicate sarcoidosis or genetic disease. The tissue signal must be interpreted in light of renal function, technical quality and anatomical distribution.

CT and magnetic resonance also assess pericardial thickness, calcifications and inflammation. A normal pericardium does not exclude constriction, just as a thickened pericardium does not prove that it is responsible for the physiology; dynamic signs of ventricular interdependence and dissociation between intrathoracic and intracardiac pressures are needed. Pericardial structure becomes meaningful only when it matches hemodynamic behavior.

Right and left heart catheterization is reserved for cases in which the distinction remains uncertain or pulmonary pressure and vascular resistance must be quantified. Restriction and constriction share elevated diastolic pressures and a dip-and-plateau pattern, whereas respiratory discordance of ventricular systolic pressures supports constriction and concordance supports restriction. Simultaneous invasive respiratory analysis is more useful than rigid cutoffs based on simple pressure equalization.

Therapeutic decisions guided by the cause

Congestion control is based on loop diuretics, possibly combined with agents acting at other nephron segments in resistant patients, with monitoring of weight, blood pressure, sodium and renal function. Excessive preload reduction may abruptly decrease output in stiff ventricles, whereas residual congestion perpetuates organ injury. The euvolemic window is narrow and requires clinical titration rather than automatic dosing.

Prognostic drugs validated in heart failure with reduced ejection fraction cannot be indiscriminately transferred to restriction with fixed output and low blood pressure. Beta-blockers or other rate-slowing drugs may be useful in selected scenarios but reduce output or exercise tolerance in others; vasodilators may cause hypotension. Conventional therapy should be adapted to etiology, rhythm, systolic function and individual tolerance.

Atrial fibrillation is treated with consideration of the importance of atrial contraction and high thromboembolic risk. Cardioversion and rhythm control may provide symptomatic benefit, but recurrences and advanced atrial disease are common; before cardioversion, the search for thrombi must be particularly meticulous. Individualized anticoagulation follows rhythm, type of cardiomyopathy and clinical risk, with often more cautious thresholds in amyloidosis.

Causal therapy radically changes the prognosis of some forms: rapid suppression of the plasma cell clone in AL, stabilization or silencing of transthyretin in ATTR, iron removal in hemochromatosis, selected immunotherapy in sarcoidosis, and treatment of eosinophilia in active endomyocardial phases. Early etiologic diagnosis is not a taxonomic exercise but the main determinant of the possibility of slowing or stopping the process.

In progressive primary forms, heart transplantation is the definitive therapy, but late referral allows pulmonary hypertension and organ dysfunction to accumulate. Ventricular assist systems are technically difficult when the cavities are small and dysfunction is biventricular; they may be feasible at expert centers but are not as straightforward a bridge as in many dilated cardiomyopathies. Transplant planning must begin while options still exist.

Family, developmental age and continuity of care

A patient with an apparently primary form requires genetic counseling and testing with an appropriate panel interpreted by a team familiar with gene-disease validity and the phenotypic spectrum. Identifying a pathogenic or likely pathogenic variant enables cascade testing in relatives; a variant of uncertain significance should not be used to predict who will develop disease. Interpretive quality matters more than indiscriminate panel breadth.

First-degree relatives receive history, ECG and imaging even when the proband's genetic test is negative or uninformative because molecular sensitivity is incomplete. Starting age and intervals depend on family history and severity of the earliest case. Longitudinal screening recognizes age-dependent penetrance and limits false reassurance from a single normal examination.

In children, fatigue may present as poor growth, feeding difficulty or reduced participation in play. Markedly dilated atria and high pulmonary pressures may precede severe systolic dysfunction, whereas adult heart failure scores do not adequately describe risk. The pediatric perspective requires early assessment at cardiomyopathy and transplant centers before deterioration reduces support options.

Pregnancy, sport, work and anesthetic procedures require assessment based on cardiac output, congestion, pulmonary pressure and arrhythmias. Changes in volume and heart rate may be poorly tolerated, but a uniform prohibition does not reflect the wide variability among forms. Contextual counseling translates physiology into concrete decisions that are shared and updated over time.

Follow-up reassesses symptoms, weight, blood pressure, rhythm, biomarkers, biventricular function, valves and pulmonary pressure, adjusting frequency and methods according to etiology. New neuropathy, proteinuria, anemia or a conduction disorder may reopen the causal investigation. A dynamic diagnosis prevents the initial label from becoming a cognitive constraint when the disease provides new information.

An orderly clinical pathway

The first step is to confirm that symptoms and signs result from high filling pressures and not only from pulmonary, renal or venous comorbidities. ECG, comprehensive echocardiography and biomarkers describe the phenotype; systemic and family history define the probability of different causes. This first clinical synthesis should be explicit because it determines which subsequent tests have real informational value.

The second step distinguishes myocardial disease from constrictive pericarditis using respiratory signs, tissue Doppler and pericardial imaging, resorting to simultaneous catheterization if the data remain discordant. The stakes are high: pericardiectomy may correct constriction but does not cure restrictive myocardium and carries substantial risk. The mechanistic distinction must precede any surgical decision.

The third step characterizes the disease using magnetic resonance, monoclonal protein studies, bone scintigraphy in appropriate contexts, iron assessment, genetic testing and selective biopsy. Every result should answer a question and change a probability, avoiding indiscriminate panels that generate false positives. The diagnostic sequence reduces both therapeutic delays and unnecessary procedures.

Finally, management integrates causal therapy, control of congestion and rhythm, thromboembolic prevention, family counseling and assessment of advanced heart failure. The cardiologist, imaging specialist, geneticist, hematologist or internist, and transplant team enter at different times but communicate within the same disease model. Coordinated care is indispensable because no single discipline alone encompasses all relevant decisions.

Interpretive errors and high-impact decision points

Calling any heart failure with preserved ejection fraction restrictive is an error because obesity, hypertension, diabetes and renal disease often produce high pressures without the anatomical RCM phenotype. Conversely, requiring an extreme Doppler pattern may miss patients already treated with diuretics or examined under different loading conditions. The clinical-morphological definition should include volumes, atria, tissue, pressures and cause, keeping HFpEF syndrome and cardiomyopathy separate.

Attributing thick walls to hypertension without comparing voltages, strain, magnetic resonance and extracardiac history delays amyloidosis; immediately attributing them to amyloid without excluding HCM, Fabry disease or renal disease produces the opposite error. Thickness is the result of cells, interstitium and deposition and does not directly measure their composition. Morphology does not type etiology, and every etiologic interpretation must be demonstrated through the appropriate pathway.

A preserved medial e' velocity, septal bounce or thickened pericardium increases the probability of constriction, but none alone determines pericardiectomy. Ventilation, loading conditions and mixed disease may produce discordant data, and radiotherapy may affect both compartments. Confirmation of constriction requires a coherent respiratory mechanism and a realistic estimate of how much of the condition can be surgically corrected.

A negative biopsy may be falsely reassuring when disease is focal, the number of samples is insufficient or typing was not performed with appropriate methods. A positive biopsy can be equally misleading if it identifies an incidental deposit without linking it to the clinically diseased heart. Contextualized pathology integrates site, distribution, amount, protein and probability rather than stopping at a positive-negative dichotomy.

In risk assessment, ejection fraction tends to dominate because it is familiar and easy to measure, but in RCM cardiac output, right ventricular function, pulmonary pressure and organ status are often more informative. Even a walk test may underestimate severity in a sedentary patient who has already adapted daily life to the disease. Hidden severity emerges by comparing habitual activity, oxygen consumption, hospitalizations and escalation of therapy.

Serial data, self-care and thresholds for reassessment

The patient is educated to monitor weight, edema, blood pressure and symptoms, recognizing rapid increases, reduced urine output, syncope, persistent palpitations or pain as reasons to make contact. Excessive fluid and salt restriction may worsen hypotension and nutrition, whereas unrestricted intake promotes congestion; advice is adapted to clinical status and climate. Guided self-management reduces fluctuations without transferring complex pharmacological decisions to the patient.

Serial echocardiography should be comparable: the same measurement method, documentation of rhythm and blood pressure, biventricular assessment and complete Doppler data. A minimal change in strain or estimated pressure does not necessarily indicate progression, whereas concordant trends across several domains warrant action. Quality of comparison matters more than indiscriminate testing frequency and reduces reactions to biological or technical noise.

A hospitalization for heart failure, new atrial fibrillation, a persistent increase in biomarkers or functional decline simultaneously reopen staging and causation. New therapies or genetic reclassification may make it useful to repeat tests that were negative years earlier, but repetition should answer a defined question. The threshold for reassessment is dynamic because disease and knowledge evolve together.

Advance planning is not the same as giving up. Discussing transplantation, device preferences, family support and emergency management while the patient is stable expands options and enables decisions consistent with personal values. Proportionality of care is updated with prognosis and response, avoiding both late futile interventions and premature limitation of potentially effective treatments.